Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus platinum-etoposide chemotherapy followed by chest radiotherapy for extensive-stage small cell lung cancer
ChiCTR2100047341Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jul 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Progression-free survival and Safety. Started Jul 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100047341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047341.